Sequent Scientific Limited has announced the allotment of 1,00,000 equity shares under its Employee Stock Option Plan 2020 (SeQuent ESOP 2020) scheme. The Nomination and Remuneration Committee approved this allotment through a resolution passed by circulation on December 30, 2025.

ESOP Allotment Details

The company has issued equity shares to eligible employees under the following terms:

The newly allotted equity shares will rank pari passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

Impact on Share Capital

The allotment has resulted in an increase in the company's issued and paid-up equity share capital:

The increase represents a marginal expansion of 0.023% in the total number of outstanding equity shares.

Corporate Governance

The allotment was executed following proper corporate governance procedures, with the Nomination and Remuneration Committee exercising its authority to approve the issuance. Company Secretary and Compliance Officer Yoshita Vora signed the regulatory filing, ensuring compliance with stock exchange requirements.

The company has duly informed both BSE Limited (Scrip code: 512529) and National Stock Exchange of India Limited (Symbol: SEQUENT) about this corporate action for their records and necessary market updates.

Sequent Scientific Limited , a prominent player in the life sciences sector, has successfully completed its postal ballot process for a significant corporate transformation. The company's shareholders have overwhelmingly approved the proposed name change and related corporate actions through remote e-voting.

Postal Ballot Results and Shareholder Approval

The postal ballot voting concluded on December 28, 2025, with shareholders demonstrating strong support for the proposed changes. The voting results show exceptional approval rates across both resolutions:

Key Approved Resolutions

Shareholders approved two special resolutions through the postal ballot process:

Resolution 1: Change of company name from 'Sequent Scientific Limited' to 'Viyash Scientific Limited' along with consequential alterations in the Memorandum of Association and Articles of Association.

Resolution 2: Alteration of the Objects Clause of the Memorandum of Association to align with the company's strategic direction.

Voting Participation and Process

The postal ballot process witnessed significant participation from various shareholder categories:

The e-voting process was conducted through the National Securities Depository Limited (NSDL) platform, ensuring transparency and accessibility for all eligible shareholders.

Corporate Transformation Timeline

The postal ballot notice was dispatched on November 28, 2025, following the board's earlier approval of the name change proposal. The remote e-voting period commenced on November 29, 2025, and concluded on December 28, 2025. The resolutions are deemed to have been passed on the last date of remote e-voting.

Strategic Implications

This approval marks a significant milestone in Sequent Scientific's corporate evolution, as the company transitions to the 'Viyash Scientific Limited' identity. The name change reflects the company's strategic alignment with the Viyash brand and supports its positioning in the life sciences sector. The alteration of the Objects Clause provides the company with enhanced flexibility to pursue its business objectives under the new corporate structure.